Covered recipient · General Payments record
ANDREA T DELLARIA
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$6,452.64
- Reported across 322 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $801.07 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Celgene Corporation | $182.90 | 8 |
| PFIZER INC. | $145.30 | 8 |
| EISAI INC. | $142.85 | 2 |
| ABBVIE INC. | $132.51 | 8 |
| EMD Serono, Inc. | $86.73 | 3 |
| Abbott Laboratories | $40.55 | 2 |
| Lundbeck LLC | $27.27 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $22.33 | 1 |
| Neurocrine BioSciences, Inc. | $20.63 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $19.89 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125367862 | CMS |
| Abbott Laboratories | $20.66 | 12/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125367864 | CMS |
| ABBVIE INC. | $23.39 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103622448 | CMS |
| ABBVIE INC. | $23.33 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103622450 | CMS |
| ABBVIE INC. | $26.80 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103622452 | CMS |
| ABBVIE INC. | $24.50 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103622454 | CMS |
| ABBVIE INC. | $12.20 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103622456 | CMS |
| ABBVIE INC. | $6.58 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103622458 | CMS |
| ABBVIE INC. | $9.28 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103622460 | CMS |
| ABBVIE INC. | $6.43 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103622462 | CMS |
| Celgene Corporation | $21.89 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101107758 | CMS |
| Celgene Corporation | $14.67 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101107772 | CMS |
| Celgene Corporation | $6.39 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101107774 | CMS |
| Celgene Corporation | $29.63 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101107780 | CMS |
| Celgene Corporation | $15.39 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101107784 | CMS |
| Celgene Corporation | $32.48 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101107792 | CMS |
| Celgene Corporation | $28.51 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101107790 | CMS |
| Celgene Corporation | $33.94 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101107802 | CMS |
| Eisai Inc. | $121.14 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110729217 | CMS |
| Eisai Inc. | $21.71 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110729219 | CMS |
| EMD Serono, Inc. | $31.51 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120213478 | CMS |
| EMD Serono, Inc. | $32.33 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120247585 | CMS |
| EMD Serono, Inc. | $22.89 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120265539 | CMS |
| Lundbeck LLC | $27.27 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145909793 | CMS |
| Neurocrine Biosciences, Inc. | $20.63 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150855986 | CMS |
| Novartis Pharmaceuticals Corporation | $22.33 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086837559 | CMS |
| PFIZER INC. | $18.78 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131572431 | CMS |
| PFIZER INC. | $19.89 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131690912 | CMS |
| PFIZER INC. | $19.46 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131565788 | CMS |
| PFIZER INC. | $19.46 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131692793 | CMS |
| PFIZER INC. | $25.21 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131591940 | CMS |
| PFIZER INC. | $25.64 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131684861 | CMS |
| PFIZER INC. | $8.76 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132072198 | CMS |
| PFIZER INC. | $8.10 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132123695 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.